Amgen Inc. (AMGN) Return on Invested Capital (ROIC): 13.16%
Is Amgen Inc.’s return on invested capital (ROIC) high or low?
Amgen Inc.'s return on invested capital (ROIC) of 13.16% is in line with its 5-year average of 12.80%, around the middle of its 5-year range (8.42%–16.72%).
The return on invested capital (ROIC) for Amgen Inc. (AMGN) is 13.16% as of Tuesday, June 9, 2026. It is above its 12-month average by 19.26% (11.04%).
AMGN Return on Invested Capital (ROIC) Chart
AMGN Average Return on Invested Capital (ROIC) Chart
AMGN Current vs Average Return on Invested Capital (ROIC) Chart
AMGN Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
13.16%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
11.04%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
11.80%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
12.80%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
12.27%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
11.53%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
11.69%
CURRENT VS TTM AVG
+19.26%
CURRENT VS 3Y AVG
+11.50%
CURRENT VS 5Y AVG
+2.84%
CURRENT VS 10Y AVG
+7.22%
CURRENT VS 15Y AVG
+14.09%
CURRENT VS 20Y AVG
+12.57%
AMGN Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amgen Inc. (AMGN) | — | 13.16% | 11.04% | 11.80% | 12.80% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 7.58% | 7.80% | 8.16% | 9.10% |
| Abbott Laboratories (ABT) | $158.94B | 8.43% | 9.16% | 9.70% | 9.86% |
| Gilead Sciences, Inc. (GILD) | $155.82B | 21.53% | 11.95% | 11.58% | 9.92% |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 13.71% | 12.85% | 12.25% | 11.92% |
| Pfizer Inc. (PFE) | $146.36B | 8.84% | 9.06% | 10.60% | 10.43% |
| Danaher Corporation (DHR) | $133.37B | 5.72% | 5.90% | 6.54% | 6.70% |
| CVS Health Corporation (CVS) | $123.84B | 4.72% | 4.17% | 4.46% | 4.93% |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 13.90% | 13.75% | 11.92% | 10.17% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 18.12% | 10.38% | 14.75% | 17.51% |
Capital Efficiency
ROIC
13.2%
ROE
89.1%
Amgen Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Amgen Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Amgen Inc. (AMGN)?
- The return on invested capital (ROIC) for AMGN stock is 13.16%.
- Is Amgen Inc.'s return on invested capital (ROIC) high or low?
- Amgen Inc.'s return on invested capital (ROIC) of 13.16% is in line with its 5-year average of 12.80%, around the middle of its 5-year range (8.42%–16.72%).
- What is the TTM average return on invested capital (ROIC) for Amgen Inc. (AMGN)?
- The TTM average return on invested capital (ROIC) for AMGN stock is 11.04%.
- What is the 3Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?
- The 3Y average return on invested capital (ROIC) for AMGN stock is 11.80%.
- What is the 5Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?
- The 5Y average return on invested capital (ROIC) for AMGN stock is 12.80%.
- What is the 10Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?
- The 10Y average return on invested capital (ROIC) for AMGN stock is 12.27%.
- What is the 15Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?
- The 15Y average return on invested capital (ROIC) for AMGN stock is 11.53%.
- What is the 20Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?
- The 20Y average return on invested capital (ROIC) for AMGN stock is 11.69%.
Amgen Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 13.16% |
| 2024-12-31 | 8.91% |
| 2023-12-31 | 8.42% |
| 2022-12-31 | 16.72% |
| 2021-12-31 | 13.69% |
| 2020-12-31 | 15.88% |
| 2019-12-31 | 16.66% |
| 2018-12-31 | 15.74% |
| 2017-12-31 | 2.85% |
| 2016-12-31 | 11.65% |
| 2015-12-31 | 11.33% |
| 2014-12-31 | 9.15% |
| 2013-12-31 | 9.33% |
| 2012-12-31 | 9.95% |
| 2011-12-31 | 8.86% |
| 2010-12-31 | 12.25% |
| 2009-12-31 | 13.63% |
| 2008-12-31 | 12.80% |
| 2007-12-31 | 10.44% |
| 2006-12-31 | 9.84% |
| 2005-12-31 | 14.24% |
| 2004-12-31 | 8.88% |
| 2003-12-31 | 9.30% |
| 2002-12-31 | -3.41% |
| 2001-12-31 | 18.35% |
| 2000-12-31 | 20.06% |
| 1999-12-31 | 27.72% |
| 1998-12-31 | 27.27% |
| 1997-12-31 | 29.01% |
| 1996-12-31 | 28.88% |
Related Metrics
About Amgen Inc.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Bradway